CD4 and intrahepatic cholangiocarcinoma: Previous work on the immune landscape in intrahepatic cholangiocarcinoma showed an immunosuppressive environment with low numbers of CD3 and CD4 to be correlated with reduced long-term outcomes [34] and low expression of PD-1 to be associated with an improved oncological survival [35,36,37].